OncoMatch/Clinical Trials/NCT06985147
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Is NCT06985147 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies DISC-3405 for polycythemia vera (pv).
Treatment: DISC-3405 — This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).
Check if I qualifyExtracted eligibility criteria
Cancer type
Myeloproliferative Neoplasm
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: phlebotomy
At least 3 phlebotomies in 26 weeks before Screening or at least 5 phlebotomies in 52 weeks before Screening. At least 1 phlebotomy must be within the 12 weeks prior to Screening.
Cannot have received: busulfan (busulfan)
Received busulfan ... within 7 months prior to Screening.
Cannot have received: pipobroman (pipobroman)
Received ... pipobroman ... within 7 months prior to Screening.
Cannot have received: phosphorus-32 (phosphorus-32)
Received ... phosphorus-32 within 7 months prior to Screening.
Cannot have received: hepcidin inducing agent
Previous use of other hepcidin inducing agents that may impact TMPRSS6 expression are not allowed.
Lab requirements
Blood counts
HCT <45% or HCT <48% if followed by a phlebotomy within 2 weeks, white blood cells 4000/μL to 20,000/μL (inclusive), and platelets 100,000/μL to 1,000,000/μL (inclusive).
Kidney function
Significant renal dysfunction, evidenced by estimated glomerular filtration rate of <30 mL/min/1.73 m2 at the Screening visit, as assessed locally.
Complete blood count values at Screening of HCT <45% or HCT <48% if followed by a phlebotomy within 2 weeks, white blood cells 4000/μL to 20,000/μL (inclusive), and platelets 100,000/μL to 1,000,000/μL (inclusive). Significant renal dysfunction, evidenced by estimated glomerular filtration rate of <30 mL/min/1.73 m2 at the Screening visit, as assessed locally.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona · Phoenix, Arizona
- USC Norris Comprehensive Cancer Center · Los Angeles, California
- UCLA Health · Los Angeles, California
- Keck Medicine of USC - Cancer Clinic- Newport Beach · Newport Beach, California
- Mayo Clinic in Florida · Jacksonville, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify